Why do patients get stem cell therapy outside the U.S.?

The FDA's 21 CFR 1271 doesn't ban cell therapy, but a clinic that wants to use cultured donor (allogeneic) umbilical-cord MSCs to modulate inflammation in a joint fails three of its four rules at once. That clinic must run a multi-year clinical trial under an IND, wait for someone else to do so, or operate outside the U.S., which is why some patients travel.

Read the four articles

Four rules in 21 CFR 1271 shape every U.S. stem cell clinic.

The FDA's 21 CFR 1271 doesn't ban cell therapy. It carves out a corridor inside which a cell preparation does not require Investigational New Drug authorization. Four conditions, read together. Cross any one of them, and you're in drug-approval territory: a median of about 8 years from first filing to approval, for each indication.

  1. Minimally manipulated.

    You may centrifuge cells. You may wash them. You may not grow them in culture, expand them, or change what they do. The line lives at 21 CFR 1271.3(f) "minimal manipulation."

    CFR 21 § 1271.10(a)(1)

  2. Homologous use.

    The cells must be used for the same biological function they performed in the donor. Bone graft to bone repair, yes. Fat-derived stromal cells to joint cartilage, no. The FDA's first court case against a U.S. clinic, in 2012, was over cultured bone marrow cells. The two since then were over fat-derived cells.

    CFR 21 § 1271.10(a)(2)

  3. Not combined.

    The cells must stand alone. A saline carrier or a cryoprotectant is fine. Mix in a growth factor, a steroid, an exosome cocktail, or a synthetic scaffold, and the result is a combination product, evaluated as a drug.

    CFR 21 § 1271.10(a)(3)

  4. Autologous, or no systemic effect.

    If the cells act on the whole body or stay biologically active, they must come from the patient, or a first- or second-degree blood relative. Allogeneic preparations given systemically, including the umbilical-cord MSCs that underpin most of the modern evidence base, have no §361 path.

    CFR 21 § 1271.10(a)(4)

The corollary, not the conspiracy. A clinic that wants to use cultured allogeneic umbilical-cord MSCs to modulate inflammation in a joint, a protocol with strong peer-reviewed evidence, fails three of the four prongs at once, and must either run a multi-year clinical trial under an IND, wait for someone else to do so, or operate outside the U.S. perimeter. There is no quiet way through.

Is the FDA the problem?

Most clinics open this conversation with a complaint about the FDA. We won't, because it isn't accurate. The FDA's framework for cell and tissue products is, by global standards, careful, sober, and well-considered.

It is also calibrated to a very specific question:

under what conditions may a company sell a new biological product, at scale, to American patients?

The first question takes years of clinical trials to answer for each indication: a median of about 8 years from first filing to approval.

That question is not the same as the one most cell-therapy patients are actually asking, which is closer to:

can a physician use a well-characterized cell preparation, in a single supervised procedure, in my body, today?

The second question is, in some countries, answered under that country's own health regulator.

In Mexico, that care is regulated by COFEPRIS. It isn't a loophole, and we won't describe it that way. You won't find, in the next four articles, the argument that the FDA is conspiring against you. You will find the argument that the FDA is doing one job, and that the job it is doing is not the one your situation may need done.

Three numbers that explain the gap.

What is in the vial at a U.S. stem cell clinic?

The rules above force a particular kind of workaround, but they do not police the word on the brochure. A U.S. clinic can legally call almost anything a "stem-cell therapy" as long as the underlying product is registered under the right HCT/P pathway. What ends up in the syringe is often something more modest.

  • Amniotic and umbilical-cord products, sold as "amniotic stem cells" or "Wharton's jelly," are typically processed and then frozen or freeze-dried before they reach the clinic. Published lab studies from UC Davis, Cornell, and Colorado State tested commercial vials and found no functioning mesenchymal stem cells.

  • Exosomes are cell-derived vesicles. They are not cells, and they cannot self-renew or differentiate. Clinics sometimes advertise them as "stem-cell therapy without the cells."

  • Stromal vascular fraction (SVF) from adipose tissue contains stem cells, but they are a minority population. The fraction is mostly pericytes, endothelial cells, immune cells, and connective-tissue fragments.

The honest version of the U.S. menu, then: a small fraction of clinics use viable autologous cells under one of the §361 carve-outs; a smaller fraction operates a real IND; the rest are selling something that has been frozen, sterilized, fractionated, or relabeled, with the word stem cell doing more work than the contents of the vial.

Four articles on treatment outside the U.S.

Each one stands on its own. Read in order, they build an argument; read one at a time, each answers a specific question.

  1. The FDA line, in plain English. The four-prong test the FDA uses to decide whether a cell therapy is a tissue or a drug, and why every U.S. clinic's marketing language is shaped by it.
  2. The U.S. stem cell clinic landscape. What the clinics offer, where they cluster, and the regulatory line they all operate on.
  3. Clinical trial vs. treatment abroad. A decision aid for the person who has just discovered there are U.S. trials for their condition and is trying to figure out whether to wait for one, apply to one, or pay for treatment elsewhere now.
  4. Is medical tourism safe? Medical tourism's safety record is not one number: it's a function of procedure, country, facility, and how the trip was organized.

Five things this section will not do.

An editorial discipline, not a marketing one. Read it once before you start: it'll tell you whether this section is for you.

  1. The argument that the FDA is corrupt.

    It isn't. It's slow, conservative, and structured around a question that does not match every patient situation. Those are three different things.

  2. Testimonials from patients who left the country.

    The library is research-grade. Patient stories live, with permission and disclosure, on a separate page. They do not belong in an explanation of regulation.

Read moreShow less

  1. "All you need to know in ten minutes."

    If a section on regulation could be reduced to ten minutes, the regulation wouldn't be doing much.

  2. An attack on U.S. clinicians who decline to treat.

    Most of them are right not to. The article on the U.S. landscape maps what the clinics offer and the regulatory line they all operate on.

  3. A claim that Mexico is better.

    Mexico is different, in ways that make this kind of therapy more accessible right now. That is the specific claim. Section 2, Why Mexico

Start with the framework. It pays back the rest.

If you're going to read one article in this section, read this one. Every other article in the library leans on it, and most of the questions we get on consult calls trace back to one of the four rules it explains.

Read the FDA line Back to the Learn library